Cargando…

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Liqin, Jia, Gang, Lu, Lingeng, Ma, Wenxue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320700/
https://www.ncbi.nlm.nih.gov/pubmed/35877249
http://dx.doi.org/10.3390/curroncol29070389
_version_ 1784755855662514176
author Yao, Liqin
Jia, Gang
Lu, Lingeng
Ma, Wenxue
author_facet Yao, Liqin
Jia, Gang
Lu, Lingeng
Ma, Wenxue
author_sort Yao, Liqin
collection PubMed
description Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.
format Online
Article
Text
id pubmed-9320700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93207002022-07-27 Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Yao, Liqin Jia, Gang Lu, Lingeng Ma, Wenxue Curr Oncol Review Neoadjuvant chemotherapy (NACT) was developed with the aims of shrinking tumors or stopping cancer cells from spreading before surgery. Unfortunately, not all breast cancer patients will benefit from NACT, and thus, patients must weigh the risks and benefits of treatment prior to the initiation of therapy. Currently, the data for predicting the efficacy of NACT is limited. Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT. MDPI 2022-07-12 /pmc/articles/PMC9320700/ /pubmed/35877249 http://dx.doi.org/10.3390/curroncol29070389 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yao, Liqin
Jia, Gang
Lu, Lingeng
Ma, Wenxue
Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title_full Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title_fullStr Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title_full_unstemmed Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title_short Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
title_sort breast cancer patients: who would benefit from neoadjuvant chemotherapies?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320700/
https://www.ncbi.nlm.nih.gov/pubmed/35877249
http://dx.doi.org/10.3390/curroncol29070389
work_keys_str_mv AT yaoliqin breastcancerpatientswhowouldbenefitfromneoadjuvantchemotherapies
AT jiagang breastcancerpatientswhowouldbenefitfromneoadjuvantchemotherapies
AT lulingeng breastcancerpatientswhowouldbenefitfromneoadjuvantchemotherapies
AT mawenxue breastcancerpatientswhowouldbenefitfromneoadjuvantchemotherapies